CSHL News Release
CSHL principal investigator Adrian Krainer was awarded together with C. Frank Benett from Ionis Pharmaceuticals the 2019 Breakthrough Prize in Life Sciences for the development of nusinersen (trade name Spinraza). Nusinersen is an antisense oligonucleotide drug for the treatment of Spinal Muscular Atrophy which received FDA approval in 2016.
The NCCR RNA & Disease congratulates Adrian Krainer and would like to thank him for serving as a member of its Scientific Advisory Board.